V. A. Bankole

V. A. Bankole

Auto-generated profile, based on publicly available information

V. A. Bankole

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2025 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
MVM. S. Vasilyeva
M. S. Vasilyeva
IKI. I. Kalinina
I. I. Kalinina
DVD. A. Venyov
D. A. Venyov
SLSvetlana Lebedeva
Svetlana Lebedeva
VBV. A. Bankole
V. A. Bankole
ОВОльшанская Ю. В.
Ольшанская Ю. В.
In the past decades, significant advancements have been made in the treatment of children with acute myeloid leukemia (AML) with the introduction of more effective treatment regimens, extended indications for hematopoietic stem cell transplantation as well as better supportive therapy and prophylaxis of infectious complications. Nevertheless, an improvement in treatment outcomes is still an important goal. One of the key ways to enhance treatment effectiveness is risk stratification of AML patients based on molecular and genetic characteristics of the disease. A multicenter treatment protocol (the AML-MRD-2018 protocol) was developed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Our study includes 525 patients from 54 Russian hospitals who underwent treatment from November 2018 to December 2023. A total of 205 patients with a median age of 8.9 years (1 month – 17.6 years) were re-stratified to the intermediate-risk group. The 3-year overall and event-free survival for this group was 77% and 47%, respectively. The patients with biallelic CEBPA (dCEBPA) mutations had the most favorable prognosis. In the intermediate-risk group, early death before remission occurred in 6% of the patients; 8% of the patients died in first remission. Death of progressive disease occurred in 32% of all the deceased patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation.

26 March 2025 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
AIA. B. Itov
A. B. Itov
YOYu. V. Olshanskaya
Yu. V. Olshanskaya
IKI. I. Kalinina
I. I. Kalinina
EZElena Zerkalenkova
Elena Zerkalenkova
MGM. V. Gaskova
M. V. Gaskova
ОВОльшанская Ю. В.
Ольшанская Ю. В.
Internal tandem duplications in the FLT3 gene (FLT3-ITD) are common in acute myeloid leukemia (AML) in adults (25–35%) and less common in children (15–17%) and, in the absence of therapy with specific inhibitors, are predictors of a poor prognosis. However, this unfavorable impact has been demonstrated mainly in AML with a normal karyotype in the absence of mutations in the NPM1 gene, or in the presence of a combination of mutations in the NPM1 gene and FLT3-ITD with a high allele ratio ( 0.5). Our study shows a high genetic heterogeneity in the patients with FLT3-ITD and its unfavorable prognostic impact in all the AML subgroups. The presence of FLT3-ITD worsens disease outcomes in the group of patients with a normal karyotype (the 2-year event-free survival (EFS) – 32%, overall survival (OS) – 55%), irrespective of the ratio of mutated to wild-type allele and the presence of mutations in the NPM1 gene. In the group of patients with markers of a favorable prognosis, the presence of FLT3ITD was associated with reduced rates of the 2-year EFS (45%; 95% CI 26–78%) and OS (43%; 95%CI 22–83%), as well as with the resistance to FLT3 inhibitors during relapse therapy. In the groups of patients with intermediate and unfavorable risk markers, the presence of FLT3-ITD was associated with a high resistance to induction therapy (57.9% and 55%, respectively). However, the addition of FLT3 kinase inhibitors to salvage therapy and a high rate of first-line hematopoietic stem cell transplantation in combination with FLT3 inhibitors as maintenance therapy in these groups significantly improved the 2-year OS rate (68% vs 62%, respectively). The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation.

26 March 2025 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
SLS. A. Lebedeva
S. A. Lebedeva
IKI. I. Kalinina
I. I. Kalinina
YOYu. V. Olshanskaya
Yu. V. Olshanskaya
AKA. N. Kazakova
A. N. Kazakova
VBV. A. Bankole
V. A. Bankole
ОВОльшанская Ю. В.
Ольшанская Ю. В.
Acute myeloid leukemia (AML) with KMT2A rearrangements is one of the most common AML subtypes in children. KMT2A rearrangements are extremely heterogeneous because of different breakpoint locations in the DNA of this gene in combination with a large number of various partner genes. Patients with KMT2A-rearranged AML are typically stratified into a high-risk group. However, there are reports of different prognostic significance of different rearrangements of this gene found both in Russian and international literature. For example, several studies including both adults and children suggested that AML with t(1;11)(q21;q23.3)/KMT2A::MLLT1 and t(9;11)(q21;q23.3)/KMT2A::MLLT3 translocations had a more favorable prognosis. However, these findings failed to be reproduced in other studies. What is more, a number of studies stated that the prognosis of survival in patients aged 0–24 months affected by KMT2A-rearranged acute leukemia may depend not only on the partner gene but also on the location of a breakpoint in the KMT2A gene, while also saying that patients with a breakpoint in intron 11 have the worst prognosis. Here, we aimed to evaluate the prognostic significance of KMT2A rearrangements in children with AML. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia. We concluded that specific partner gene and breakpoint location did not have any significant influence on treatment outcomes in children with KMT2A-rearranged AML who had been treated according to the AML-MRD-2018 protocol. These findings may indicate that such patients should be stratified into a high-risk group irrespective of the involved partner gene and breakpoint location.

4 July 2020 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
ABA. V. Bankole
A. V. Bankole
ECE. A. Chernyak
E. A. Chernyak
Red cell pyruvate kinase deficiency is the most common glycolytic defect causing congenital nonspherocytic hemolytic anemia. Pyruvate kinase is the enzyme involved in the last step of glycolysis – the transfer of a phosphate group from phosphoenolpyruvate producing the enolate of pyruvate and ATP (50 % of total energy ATP of erythrocytes). ATP deficiency directly shortened red cell lifespan. Affected red blood cells are destroyed in the splenic capillaries, leading to the development of chronic hemolytic anemia. It is an autosomal recessive disease, caused by homozygous and compound heterozygous mutations in the PKLR gene. There are no exact data on the incidence of pyruvate kinase deficiency, but the estimated frequency varies from 3: 1,000,000 to 1:20,000. The clinical features of the disease and the severity are highly variable. Diagnosis of pyruvate kinase deficiency is based on the determination of pyruvate kinase activity and molecular genetic study of the PKLR gene. The variety of clinical manifestations, possible complications, as well as the inaccessibility of diagnostic methods complicate the diagnosis.

14 April 2026 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
GNG. A. Novichkova
G. A. Novichkova
APA. V. Popa
A. V. Popa
ZAZ. A. Abashidze
Z. A. Abashidze
MVM. S. Vasilyeva
M. S. Vasilyeva
OAO. V. Aleinikova
O. V. Aleinikova
AMA. A. Maschan
A. A. Maschan
Introduction. Acute myeloid leukemia (AML) is the second most prevalent type of blood malignancy in children that accounts for 15–20% of all pediatric leukemia cases. Before 2018, large-scale prospective studies of AML in children in the Russian Federation were constrained by the absence of both a central pathology review system and centralized monitoring of minimal residual disease (MRD). To address these issues, the national protocol AML-MRD-2018 (NCT03846362) was developed and initiated by the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Materials and methods. This study included 631 patients from 54 clinical facilities across 48 regions of the Russian Federation. Central pathology review was performed at two institutions: the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow) and Yekaterinburg Regional Children's Clinical Hospital. Risk group stratification was performed in two steps: initially it was based on molecular and genetic characteristics of blast cells, and then (for intermediate risk group) – on response to treatment assessed by MRD testing. Criteria for primary refractoriness and the transfer of patients to a high-risk group were blast cell count (assessed morphologically and immunophenotypically) 5% after induction and MRD ≥ 0.1% after the first course of consolidation. The final stratification was as follows: 67 standard-risk patients, 251 intermediate-risk patients, and 313 high-risk patients. Results. Response to induction therapy was assessable in 580 patients; complete remission was achieved in 84.3% of the cases (n = 489). Treatment effectiveness varied significantly across the risk groups: it was 100% in the standard-risk group (all the patients achieved MRD-negative remission), 91.5% in the intermediate-risk group and 72.9% in the high-risk group (which had the highest proprotion of refractory and MRD positive patients). The first cycle of consolidation therapy according to the protocol was given to 385 patients from the intermediate- and high-risk groups; MRD assessment was performed in 348 cases. MRD-negative remission was achieved in 196 (96%) out of 204 MRD-assessed patients in the intermediate-risk group and in 129 (90%) out of 144 MRD-assessed patients in the high-risk group. The 3-year treatment outcomes in the whole cohort of patients (n = 631) were the following: the overall survival (OS) reached 71% (95% confidence interval (CI) 68–76), the event-free survival (EFS) was 44% (95% CI 40–48), the cumulative risk of relapse (CRR) was 36% (95% CI 31–41). There were significant differences in these parameters between the risk-groups: standard-risk group (n = 67): OS – 84%, EFS – 66%, CRR – 24%; intermediate-risk group (n = 251): OS – 77%, EFS – 50%, CRR – 38%; high-risk group (n = 313): OS – 64%, EFS – 34%, CRR – 37%. Over the period of observation, a total of 255 allogeneic hematopoietic stem cell transplantations (HSCT) were performed. The most common HSCTs were from haploidentical related donors (n = 180; 70%), the graft sources were peripheral blood stem cells (n = 138) and bone marrow (n = 87). The median time from start of therapy to HSCT was 5 months. The 2-year EFS after HSCT was 65% and the 2-year OS post-HSCT was 75%. Conclusion. To date, the potential of universal chemotherapy protocols for AML has been exhausted. Further improvements in treatment outcomes are only possible through the implementation of individualized treatment strategies based on molecular genetic profiling. Promising approaches include the addition of FLT3 inhibitors, gemtuzumab ozogamicin, venetoclax; the inclusion of menin inhibitors in leukemias with KMT2A rearrangements; the integration of hypomethylating agents in the treatment of patients with CBF-AML.

29 January 2026 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ESElena V. Suntsova
Elena V. Suntsova
DBD. D. Baydildina
D. D. Baydildina
LKLili A. Khachatryan
Lili A. Khachatryan
MSM. N. Sadovskaya
M. N. Sadovskaya
VMV. E. Matveev
V. E. Matveev
БДБайдильдина Дина Дамировна
Байдильдина Дина Дамировна
Introduction. Immune thrombocytopenia (ITP) is characterized by increased platelet destruction and suboptimal platelet production, which results in reduced platelet counts in peripheral blood and bleeding of varying severity. In children with ITP, remission is often achieved with first-line therapy or even spontaneously. Thrombopoietin receptor agonists and rituximab are considered modern therapies of choice in severe and/or chronic course of the disease, splenectomy is performed less frequently. Despite the favorable prognosis, some patients may exhibit resistance to initial therapy and a small proportion of patients fail to respond to several courses of first- and/or second-line ITP-directed therapies, thus developing refractory ITP. The management of patients with resistant and refractory ITP is a clinical challenge. Clinical cases. The article presents seven clinical cases of severe ITP of varying duration. The patients aged 1.5 to 17 years received combination therapy due to unsatisfactory therapeutic response in order to prevent severe hemorrhagic complications. The article describes the clinical presentation and different therapeutic approaches, discusses modern possibilities and combined treatment regimens for resistant and refractory ITP in children. Conclusion. Overall, current studies of pathogenesis and the development of guidelines for managing ITP patients aim to optimize treatment, particularly for resistant, refractory, severe persistent and chronic forms of the disease, reduce the risk of bleeding, increase the likelihood of achieving long-term remission, and improve the quality of life of patients and their families.